| 0.6402 -0.013 (-2.05%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.91 |
1-year : | 1.03 |
| Resists | First : | 0.78 |
Second : | 0.88 |
| Pivot price | 0.71 |
|||
| Supports | First : | 0.62 | Second : | 0.51 |
| MAs | MA(5) : | 0.65 |
MA(20) : | 0.73 |
| MA(100) : | 1.51 |
MA(250) : | 5.8 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 8.6 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 55 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNPX ] has closed above bottom band by 18.4%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.7 |
| Low: | 0.63 - 0.63 | 0.63 - 0.64 |
| Close: | 0.63 - 0.64 | 0.64 - 0.65 |
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Fri, 12 Jun 2026
Genprex Received Notice of Delisting - TradingView
Fri, 12 Jun 2026
Genprex (NASDAQ: GNPX) confronts Nasdaq delisting risk after sub-$1 bid price - Stock Titan
Fri, 05 Jun 2026
Genprex (GNPX) files shelf registration to sell up to $250M in securities - Stock Titan
Fri, 05 Jun 2026
GNPX Should I Buy - Intellectia AI
Tue, 26 May 2026
Tumor protein pattern linked to longer control on lung cancer gene therapy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 506 (K) |
| EPS | -5.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.2 % |
| Return on Equity (ttm) | -160.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|